ChristopherBrentBentonMD

PubMed

• Nonspecific Signs and/or Symptoms of Cancer: A Retrospective, Observational Analysis from a Secondary Care, US Community Oncology Dataset.
  Christopher B Benton, Ding He, Karen Todoroff, Marie V Coignet, Ying Luan
  Current Oncology. 2024-06-25
• 2 citations
  A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
  Sudhir Manda, Bertrand M Anz 3rd, Christopher Benton, E Randolph Broun, Habte A Yimer
  Hematological Oncology. 2024-05-01
• 1 citations
  Co-management strategies for acute myeloid leukemia patients in the community setting.
  Christopher Benton, Michael R Grunwald, Hana Safah, Margaret Kasner
  Frontiers in Oncology. 2022-01-01

Abstracts/Posters

• Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Bone Marrow Fibrocytes Overexpress Gli1 Oncogenic Transcription Factor in Primary Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Diverse Landscape of TET2 Variants in MDS and AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all